Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Barbara A. Konkle, MD, Kimo Stine, MD, Nathan Visweshwar, MD, Thomas J. Harrington, MD, Andrew D. Leavitt, MD, Adam Giermasz, MD PhD, Steven Arkin, MD, Gregory Di Russo, MD, Ashley Snyder, PharmD, MPH, Adrian Woolfson, MD PhD, Didier Rouy, MD PhD

Blood (2019) 134 (Supplement_1): 2060.

https://doi.org/10.1182/blood-2019-122143

Published: 2019

Journal Articles

Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia

Angela R. Smith, MD MS, Gary J. Schiller, MD, Gregory M Vercellotti, MD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Erica B. Esrick, MD, David A. Williams, MD, Weston P. Miller, MD, Adrian Woolfson, MD PhD, Mark C. Walters, MD

Blood (2019) 134 (Supplement_1): 3544.

https://doi.org/10.1182/blood-2019-125743

Published: 2019

Journal Articles

Drug-Insensitive CML Stem/Progenitor Cells Highly Express Key Regulators of the Hedgehog Pathway and Inhibition of the Hedgehog Pathway Enhances Their Response to TKI Treatment

Kelly A. Turner, BSc, Katharina Rothe, PhD, Adrian Woolfson, MD PhD, Xiaoyan Jiang, MD PhD

Blood (2016) 128 (22): 4236.

https://doi.org/10.1182/blood.V128.22.4236.4236

Published: 2016

Journal Articles

Effectively Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders With Combination Treatments Of JAK2 and ABL Inhibitors In Vitro and In Vivo

Hanyang Lin, MSc, Min Chen, PhD, Katharina Rothe, MSc, Matthew V Lorenzi, PhD, Adrian Woolfson, BM BCh, PhD, Xiaoyan Jiang, MD, PhD

Blood (2013) 122 (21): 1474.

https://doi.org/10.1182/blood.V122.21.1474.1474

Published: 2013

Journal Articles

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Animesh Pardanani, MBBS, PhD, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, FRACP, PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Kebede Begna, MD, Hiroyuki Yoshitsugu, PhD, Toni Ann Gestone, PhD, Penny Phillips, PhD, Guan Xing, PhD, Gerson Peltz, MD, MPH, Matthew V Lorenzi, PhD, Leila Alland, MD, Adrian Woolfson, BM BCh, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 664.

https://doi.org/10.1182/blood.V122.21.664.664

Published: 2013

Journal Articles

Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Hanyang Lin, Katharina Rothe, Matthew V Lorenzi, PhD, Adrian Woolfson, BM BCh, PhD, Xiaoyan Jiang, MD, PhD

Blood (2012) 120 (21): 1339.

https://doi.org/10.1182/blood.V120.21.1339.1339

Published: 2012

Journal Articles

Targeting the CML Stem/Progenitor Cell with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Hanyang Lin, Matthew Lorenzi, PhD, Adrian Woolfson, PhD, Xiaoyan Jiang, MD, PhD

Blood (2011) 118 (21): 2743.

https://doi.org/10.1182/blood.V118.21.2743.2743

Published: 2011

Journal Articles

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Xiaoyan Jiang, MD, PhD, Hannah Grant, PhD, Justin Stebbing, MD, PhD, Letizia Foroni, MD, Charles Craddock, BM, MRCP, MRCPah, MD, Mike Griffiths, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, MD, PhD, Jamshid S. Khorashad, MD, PhD, Gareth Gerrard, MD, PhD, Lihui Wang, MD, PhD, Julie Irving, PhD, Meng Wang, PhD, Loraine Karran, MD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Donna L. Forrest, MD, Karen Page, MA, PhD, Connie J. Eaves, PhD, Adrian Woolfson, PhD

Blood (2010) 116 (21): 3397.

https://doi.org/10.1182/blood.V116.21.3397.3397

Published: 2010

Journal Articles

Conservation of unique cell-surface CD antigen mosaics in HIV-1–infected individuals

Adrian Woolfson, Justin Stebbing, Brian D. M. Tom, Kerryn J. Stoner, Walter R. Gilks, David P. Kreil, Stephen P. Mulligan, Larissa Belov, Jeremy S. Chrisp, Will Errington, Adrian Wildfire, Wendy N. Erber, Mark Bower, Brian Gazzard, Richard I. Christopherson, Mike A. Scott

Blood (2005) 106 (3): 1003–1007.

https://doi.org/10.1182/blood-2004-12-4642

Published: 2005

NARROW

Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

Preliminary Results of a Phase 1/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia

Drug-Insensitive CML Stem/Progenitor Cells Highly Express Key Regulators of the Hedgehog Pathway and Inhibition of the Hedgehog Pathway Enhances Their Response to TKI Treatment

Effectively Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders With Combination Treatments Of JAK2 and ABL Inhibitors In Vitro and In Vivo

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Targeting the CML Stem/Progenitor Cell with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype.

Conservation of unique cell-surface CD antigen mosaics in HIV-1–infected individuals

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only